BEACON CRC: Patient-Reported Quality of Life Results
Episode description
This week, we'll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium: Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer; Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancers; and Dr. Zev Wainberg, of UCLA Medical Center, discusses a subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in patients with PD-L1–positive disease.
Coverage of stories discussed this week on ascopost.com:
2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium:This week, we'll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium: Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer; Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancers; and Dr. Zev Wainberg, of UCLA Medical Center, discusses a subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in patients with PD-L1–positive disease.
Coverage of stories discussed this week on ascopost.com:
2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer. Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancers. Dr. Zev Wainberg, of UCLA Medical Center, discusses a subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in patients with PD-L1–positive disease.This week, we'll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium: Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer; Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancers; and Dr. Zev Wainberg, of UCLA Medical Center, discusses a subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in patients with PD-L1–positive disease.
Coverage of stories discussed this week on ascopost.com:
2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:This week, we'll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium: Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer; Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancers; and Dr. Zev Wainberg, of UCLA Medical Center, discusses a subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in patients with PD-L1–positive disease.
Coverage of stories discussed this week on ascopost.com:
2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> 2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRCThis week, we'll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium: Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer; Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancers; and Dr. Zev Wainberg, of UCLA Medical Center, discusses a subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in patients with PD-L1–positive disease.
Coverage of stories discussed this week on ascopost.com:
2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> 2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test